Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.
Mrinal M GounderAlbiruni Abdul RazakNeeta SomaiahSant ChawlaJavier Martín-BrotoGiovanni GrignaniScott M SchuetzeBruno VincenziAndrew J WagnerBartosz ChmielowskiRobin L JonesRichard F RiedelSilvia StacchiottiElizabeth Trice LoggersKristen N GanjooAxel Le CesneAntoine ItalianoXavier García Del Muro SolansMelissa BurgessSophie Piperno-NeumannChristopher RyanMary F MulcahyCharles ForscherNicolas PenelScott H OkunoAnthony D EliasLee HartnerTony PhilipThierry AlcindorBernd KasperPeter ReichardtLore D F LapeireJean Yves BlayChristine ChevreauClaudia Maria Valverde MoralesGary K SchwartzJames L ChenHari DeshpandeElizabeth J DavisGarth NicholasStefan GröschelHelen HatcherFlorence DuffaudAntonio Casado HerráezRoberto Diaz BeveridgeGiuseppe BadalamentiMikael ErikssonChristian F MeyerMargaret von MehrenBrian Andrew Van TineKatharina S GötzeFilomena MazzeoAlexander YakobsonAviad ZickAlexander T J LeeAnna Estival GonzalezAndrea NapolitanoMark A DicksonDayana MichelChang-Ting MengLingling LiJianjun LiuOsnat Ben-ShaharDane R Van DomelenChristopher J WalkerHua ChangYosef LandesmanJatin J ShahSharon ShachamMichael G KauffmanSteven AttiaPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
expression as a predictive biomarker for selinexor in DD-LPS is warranted.